![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Lund University Hospital Sanofi-Aventis |
---|---|
Information provided by: | Lund University Hospital |
ClinicalTrials.gov Identifier: | NCT00717938 |
The endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.
Condition | Intervention | Phase |
---|---|---|
Small Cell Lung Cancer |
Drug: cisplatinum or carboplatin and e.g.etoposide. Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer |
Estimated Enrollment: | 390 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A
Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
|
Drug: cisplatinum or carboplatin and e.g.etoposide.
Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
|
B: Experimental
Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
|
Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin
Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
|
Chemotherapy will be given in accordance with local or regional guidelines but shall include a platinum drug + any topoisomerase inhibitor. Within these limits the study will accept different local variants as long as each centre remains consistent to its declared standard chemotherapy regimen. The recommended regimen is carboplatin or cisplatin plus etoposide q3 weeks for 4 cycles but up to 6 cycles is allowed. Local dosages and dose reduction schedules will be used.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lars Ek, MD | +46 46 17 73 40 | lars.ek@skane.se |
Contact: Jan Sundberg, RN | +46 46 17 70 34 | jan.sundberg@skane.se |
Sweden | |
University Hospital Department of Respiratory Medicine | Recruiting |
Lund, Sweden, 221 85 | |
Contact: Martin Wallberg, MD +46 46 17 14 56 martin.wallberg@med.lu.se | |
Contact: Jan Sundberg, RN +46 46 17 70 34 jan.sundberg@skane.se | |
Principal Investigator: Lars EK, MD |
Principal Investigator: | Lars Ek, MD | University Hospital, Lund |
Study Director: | Jan Sundberg, RN | University Hospital, Lund |
Responsible Party: | University Hospital Lund, Department of Respiratory Medicine ( Lars Ek ) |
Study ID Numbers: | EudraCT number 2007-006033-14 |
Study First Received: | July 16, 2008 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00717938 |
Health Authority: | Sweden: Medical Products Agency |
Thoracic Neoplasms Carcinoma, Neuroendocrine Carboplatin Etoposide phosphate Enoxaparin Carcinoma Neuroendocrine Tumors Carcinoma, Small Cell Neuroectodermal Tumors |
Cisplatin Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasms, Germ Cell and Embryonal Neuroepithelioma Adenocarcinoma Etoposide Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms by Histologic Type Anticoagulants Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Nerve Tissue Physiological Effects of Drugs Hematologic Agents Fibrinolytic Agents |
Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses Antineoplastic Agents, Phytogenic |